Table 1. Patient’s characteristics.

Patient no	Diagnosis	Sex	Age	Sokal score	Disease duration(months)	Response*
1	CML-AP	M	44	HR	126	MMR
2	CML-AP	F	59	HR	68	MR5
3	CML-CP	M	39	HR	62	MR5
4	CML-CP	M	23	UN	96	MMR
5	CMP-CP	M	80	IMR	44	CHR
6	CML-CP	M	65	HR	39	CHR (MMR after current ponatinib treatment)

AP—Accelerated Phase; CP—Chronic Phase; LR- low risk; IMR—intermediate risk; HR-high risk; MMR—Major Molecular Response (BCR-ABL1 ≤ 1%); MR⁵ (deep Molecular Response– 5 log reduction of BCR-ABL1 transcript levels from the standardized baseline); UN- unknown,

*–response to IFN-α individualized therapy